SYMQY (SymBio Pharmaceuticals) Beta: -0.6375 (As of Jun. 27, 2026)


SYMQY SymBio Pharmaceuticals Ltd SYMQY
36 GF Score
Price $0.56
GF Value $0.51
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Beta?

SymBio Pharmaceuticals SYMQY -12.42% 36 Beta is -0.6375 as of Jun. 27, 2026. GuruFocus rates SYMQY with a GF Score™ of 36/100 and a GF Value™ of $0.51. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), SymBio Pharmaceuticals's Beta is -0.6375.


SymBio Pharmaceuticals  (OTCPK:SYMQY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


SymBio Pharmaceuticals Beta Related Terms


SymBio Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Beta Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.54 0.31 0.20 -0.81

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.26 -0.28 -0.81 -0.87

SYMQY vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SymBio Pharmaceuticals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where SymBio Pharmaceuticals's Beta falls into.


SYMQY
36GF Score
SymBio Pharmaceuticals Ltd SYMQY
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.6375 mean?
SymBio Pharmaceuticals (SYMQY) has a Beta of -0.6375 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Beta too high?
SymBio Pharmaceuticals' current Beta is -0.6375. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Beta compare to ZTS?
SymBio Pharmaceuticals' Beta of -0.6375 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Beta is -0.6375. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Beta of -0.6375. The stock's GF Value™ is $0.51, compared to a current price of $0.56 — trading 9.4% above its estimated fair value. The current Beta is -0.6375. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Beta is -0.6375 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.56 is trading 9.4% above its estimated GF Value™ of $0.51.

Key valuation signals for SYMQY:

  • Beta: -0.6375
  • GF Value™: $0.51 vs. price of $0.56 (9.4% above fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SymBio Pharmaceuticals Business Description

Other Exchanges 4582:Japan
Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for SYMQY

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.51
GF Value